On the flip side, vaccines Prevnar and Abrysvo underperformed expectations. Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 RSV vaccine Abrysvo specifically floundered ...

Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized ... In a earnings report Tuesday, Pfizer said sales of its vaccine Abrysvo fell 62% year over year ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Pfizer is also running a phase 3 trial of Abrysvo in adults aged 18 to 59 at elevated risk of RSV disease due to chronic medical conditions, but data from that isn't due until later this year.

Pfizer filed for Japanese approval of Abrysvo for the prevention of RSV disease in the older adult setting in February.

Pfizer's vaccine against respiratory syncytial virus, or RSV, saw $198 million in revenue for the fourth quarter, down 62% from the year-earlier period. The shot, known as Abrysvo, entered the ...

Recently, Pfizer found itself in the agency's crosshairs thanks to one of its M&A plays. Now, Pfizer—which purchased neuroscience specialist Biohaven for $11.6 billion in 2022—is committing ...

Two RSV vaccines were approved for use in Australia last year by the Therapeutic Goods Administration. The Australian Government is funding Pfizer’s Abrysvo for pregnant women and, in an unusual ...

Respiratory syncytial virus (RSV) is known to cause considerable respiratory infection-related morbidity and mortality worldwide.1,2 Estimates published in 2022 from the UK highlight the ...

Likewise, Abrysvo, a vaccine against RSV, which will generate revenues of ~$750m in 2024 — up 44%. Another major revenues contributor to Pfizer's revenues — the blood-thinner Eliquis ...

Pregnant women can now get the maternal RSV vaccine, Abrysvo, for free under the National Immunisation Program (NIP), alongside ones for influenza and whooping cough. Abrysvo is available for ...